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During 2003–2006, diphtheria rates in Hyderabad, In-
dia, were higher among persons 5–19 years of age, women, 
and Muslims than among other groups. Vaccine was efﬁ  ca-
cious among those who received >4 doses. The proportion 
of the population receiving boosters was low, especially 
among Muslims. We recommend increasing booster dose 
coverage. 
D
iphtheria is a disease caused by the exotoxin pro-
duced by Corynebacterium diphtheriae. The Ex-
panded Programme of Immunization of the World Health 
Organization recommends 3 doses of the diphtheria, per-
tussis, and tetanus (DPT) vaccine starting at 6 weeks of 
age with additional doses of diphtheria vaccine in coun-
tries where resources permit (1). Many national immu-
nization programs, including the Universal Immunization 
Programme of India, offer 2 booster doses at 18 months 
and between 54 and 72 months of age. After 3 doses of 
primary vaccine, protective levels of antitoxin develop in 
94% to 100% of children (1,2). However, without booster 
doses, over time toxoid-induced antibody drops below 
protective levels (2,3).
In 2005, India contributed 5,826 (71%) of the 8,229 
diphtheria cases reported globally (4). Of the total cases 
from India, 4,161 (71%) were from the state of Andhra 
Pradesh (5). Hyderabad, the state capital, contributed 663 
(16%) of the total cases from the state (Government of 
Andhra Pradesh, unpub. data). The administrative cover-
age of primary vaccination among children 12–23 months 
of age (a performance indicator for Universal Immuniza-
tion Programme [UIP]) ranged from 98% to 100% in the 
city from 1995 through 2006. We conducted a study to 1) 
describe the epidemiology of diphtheria in terms of time, 
place, and person; 2) estimate vaccine coverage; and 3) es-
timate diphtheria vaccine efﬁ  cacy.
The Study
Diphtheria patients identiﬁ   ed in Hyderabad and 
neighboring districts are admitted to the Fever Hospital. 
Case-patients undergo a smear examination of the char-
acteristic patch of thick gray membrane and samples are 
cultured for C. diphtheriae. To describe the epidemiology 
of diphtheria, we included cases deﬁ  ned as an acute fe-
brile infection with gray-white patch in pharynx, tonsils, 
or fauces among residents of Hyderabad admitted to Fe-
ver Hospital during 2003–2006. We obtained data regard-
ing age, sex, religion, month and year of occurrence, and 
circle (municipal administrative subdivision) of residence 
from the medical records of 2,685 diphtheria case-patients 
admitted during 2003–2006. Thirty-one case-patients 
died (overall case-fatality rate 1.2%). Diphtheria occurred 
throughout the year with lower incidences during July 
and August (Figure). Annual incidence increased from 
11/100,000 to 23/100,000 from 2003 through 2006 (χ2 
trend 152; p = 0.00001). Median age of case-patients was 
17 years (range 9 months–80 years). Attack rates were 
lowest among infants, increased with age, and reached a 
maximum among children 10–14 years of age. Rates were 
higher among girls and women (Table 1). Of the 2,685 
case-patients, 70% were Muslim, who had rates 3 times 
higher than other communities. Circle-speciﬁ  c attack rates 
ranged from 17/100,000 to 25/100,000 and were highest 
in the ﬁ  rst 4 circles of the city where a predominantly 
Muslim population resided; this area accounted for 90% 
of cases in 2003–2006. During 2006, 81% of the cases 
were either smear or culture positive.
We surveyed the 7 circles of the city to estimate pri-
mary vaccination coverage among children 12–23 months 
of age, fourth diphtheria dose (DPT) among those 18–36 
months of age, and ﬁ  fth diphtheria dose (DT) among chil-
dren 54–72 months of age, respectively. We selected a 
stratiﬁ  ed sample of 658 children in each age group. Criteria 
for a completely vaccinated child were deﬁ  ned according 
to the UIP vaccination schedule by age group.
Coverage for primary vaccination, fourth, and ﬁ  fth 
doses was 90% (95% conﬁ  dence interval [CI] 89%–90%), 
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60% (95% CI 59%–60%), and 33% (95% CI 33%–34%), 
respectively. Although coverage for primary vaccination 
did not differ among Muslims and non-Muslims (cover-
age ratio 0.95, 95% CI, 0.90%–1.1%), coverage for fourth 
and ﬁ  fth doses was lower among Muslims (coverage ratios 
0.86, 95% CI 0.75%–0.99% and 0.59, 95% CI 0.5%–0.8%, 
respectively).
We compared laboratory-conﬁ  rmed  case-patients 
<10 years of age who lived in Hyderabad with age- and 
residence-matched controls. Information about educational 
status of parents, monthly family income, religion, and 
number of vaccine doses received was collected through 
interviews of mothers or guardians.  Vaccination status was 
ascertained from vaccination cards or the mother’s history 
when a card was not available. All exposures were included 
in a stepwise conditional logistic regression by using Epi 
Info (Centers for Disease Control and Prevention, Atlanta, 
GA, USA). Vaccine efﬁ  cacy (%) was calculated by using 
the 1 – odds ratio formula (6). We included all children 
in the analysis to estimate vaccine efﬁ  cacy for the ﬁ  rst 4 
doses. However, to estimate the efﬁ  cacy of 5 doses of diph-
theria vaccine, we restricted the analysis to children 5–10 
years of age because the ﬁ  fth dose of the vaccine is given 
to children >4.5 years of age.
We included 123 case-patients in the case-control 
study. Only 20 (16%) controls and 23 (19%) case-patients 
had a vaccination card. The median age of case-patients 
was 7 years and 50% were girls. Twenty-one children 
(17%) were younger than 5 years of age. When adjusted for 
religion, family income, and literacy status of parents, vac-
cine efﬁ  cacy increased from 49% (95% CI 0%–80%) for 3 
doses to 65% (95% CI 8%–87%) for 4 doses. Among chil-
dren >5 years of age, efﬁ  cacy for 5 doses was 91% (95% CI 
68%–98%) (Table 2).
Conclusions
Our results indicate that in Hyderabad, diphtheria 
mainly affected children 5–19 years of age, girls and wom-
en, and the Muslim population. Receiving a fourth and ﬁ  fth 
doses of the vaccine was needed for protection against the 
disease. Coverage of primary vaccination was adequate in 
the city whereas, coverage for the boosters was low.
Low booster coverage, especially among Muslims, 
might have inﬂ  uenced herd immunity and thereby contrib-
uted to higher attack rates among this community. This fac-
tor was likely an important reason for persistence of diph-
theria in Hyderabad. Similar phenomena were observed in 
countries where diphtheria reemerged after successful con-
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Table 1. Average yearly attack rate of diphtheria by age and sex, Hyderabad, India, 2003–2006 
Demographic characteristics  No. cases, 2003–2006  Average population, 2003–2006  Annual attack rate/100,000 population 
Age,  y 
<1 8 81,050 2
 2–4  116 240,450 12
 5–9  455 415,673 27
 10–14  530 455,426 29
 15–19  431 450,408 24
 20–44  1,054 1,583,569 17
>45 91 632,964 4
Sex 
 Male  1,153 1,983,960 15
 Female  1,532 1,875,580 20
Religion
 Non-Muslim  811 2,270,695 9
 Muslim  1,874 1,588,845 29
Total 2,685 3,859,540 17
Table 2. Number of doses of diphtheria vaccine received by diphtheria case-patients and matched controls, Hyderabad, India, 2006*
Case-patients Controls No. doses 
received <5 y of age  >5 y of age  Total <5 y of age  >5 y of age  Total
Odds ratio 
estimate
Vaccine efficacy 
estimate, % (95% CI)
0 6 20 26 2 11 13 Reference Reference
1 0 7 7 1 2 3 1.4 (0.22–8.9)  0 (0–78) 
2 2 6 8 0 2 2 2.1 (0.37–12)  0 (0–63) 
3 6 34 40 8 26 34 0.51 (0.20–1.3)  49 (0–80) 
4† 7 27 34 10 30 40 0.35 (0.13–92)  65 (8–87) 
5‡ NA 8 8 NA 31 31 0.09 (0.02–0.33)  91§ (68–98) 
*Conditional logistic regression taking into account vaccine doses, religion, family income, and parental literacy. CI,  confidence interval; NA, not 
applicable. 
†Booster at 18 mo of age. 
‡Booster at 5 y of age. 
§Vaccine efficacy among children >5 y of age; younger children could not have received that booster. trol with vaccination (2,7). Several studies have reported 
vaccine efﬁ  cacies ranging from 95% to 98% for 3 doses 
and from 90% to 99.9% for 5 doses (8,9). Two factors may 
explain the lower efﬁ  cacy observed in our study. First, 
misclassiﬁ  cation may have occurred when assessing vac-
cination status of children that mainly relied on a mother’s 
recollection of the child’s history. Second, program quality 
issues in vaccine supply or in cold-chain maintenance may 
have affected efﬁ  cacy in Hyderabad. However, an evalu-
ation of the universal immunization program conducted 
in 2006 in Hyderabad did not identify any gaps in cold-
chain maintenance in the public health sector (Government 
of Andhra Pradesh, unpub. data). Thus, we concluded that 
misclassiﬁ  cation with respect to assessment of vaccination 
status (using only the mother’s recollection) probably ex-
plains the low vaccine efﬁ  cacy that we observed.
Two factors could also explain the lower booster cov-
erage among Muslims: 1) issues concerning the offer of 
vaccine by the health services or 2) issues concerning vac-
cine demand. However, primary vaccination coverage was 
identical among Muslims and non-Muslims in Hyderabad. 
This suggests that, initially, the demand for primary vacci-
nation was identical in all communities, but that the health 
system was not able to retain the same demand for boosters 
in the Muslim community.
Our study had 2 main limitations. First, we only in-
cluded patients admitted to Fever Hospital. Patients with 
milder symptoms who might not have sought treatment at 
the hospital were not considered. This situation may have 
led to an underestimation of attack rates but would not 
have led to different conclusions about the persistence of 
the disease. Second, a large proportion of children did not 
have vaccination cards, which may also have affected our 
vaccine efﬁ  cacy estimates. We tried to address this factor 
by comparing vaccination status with the child’s develop-
mental milestones.
On the basis of our study results, we propose recom-
mendations for control of diphtheria in Hyderabad. First, 
coverage for boosters must be improved, with special em-
phasis on the 4 administrative areas with high attack rates. 
Such efforts should be conducted among the Muslim com-
munity in particular. Second, mothers must be made more 
aware of the importance of booster doses. Again, these ef-
forts should focus on the Muslim community. Third, be-
cause attack rates were high among adolescents, tetanus 
toxoid (administered to school children at 10–15 years of 
age) could be replaced with a combined tetanus-diphtheria 
vaccine. Fourth, coverage of boosters could be considered 
as performance indicators to improve the immunization 
program.
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